Peer Review History
| Original SubmissionOctober 18, 2019 |
|---|
|
PONE-D-19-29166 Prevalence of previously diagnosed diabetes and glycemic control strategies in Mexican adults: ENSANUT-2016 PLOS ONE Dear M.Sc Ramirez-Villalobos, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. We would appreciate receiving your revised manuscript by Jan 24 2020 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols Please include the following items when submitting your revised manuscript:
Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. We look forward to receiving your revised manuscript. Kind regards, Naeti Suksomboon Academic Editor PLOS ONE Journal Requirements: 1. When submitting your revision, we need you to address these additional requirements. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ 3. Thank you for stating the following financial disclosure: "No"
Please include your amended statements within your cover letter; we will change the online submission form on your behalf. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: I Don't Know ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: This study provides estimates of diabetes among Mexican adults using data from the most recent national health survey in Mexico. The topic of the study is of high importance, given how prominent diabetes and associated risk factors, like overweight and obesity, are in Mexico and the significant health, societal and economic impacts these conditions have at present. The paper can be improved by clarifying certain methodological aspects and assertions, better organizing of the results,by situating the findings in the context of any national diabetes prevention and control strategies, and adding an implications/recommendations for research and/or practice paragraph to the discussion. Abstract • There is a typo on line 26, pertaining to the year of the ENSANUT survey. • Unclear whether odds ratios are crude or adjusted for other factors. • On lines 34-36, it is unclear whether the percentages reported refer to all ENSANUT participants or only those diagnosed with diabetes. Also, if 44.9% measured their venous blood glucose, how is it possible that 69.5% were estimated as not engaging in any control strategies? The two percentages would exceed 100%. • The discussion should be based on reported results, not report new results. The authors mention activity and education, but those results are not reported in the results section. • The discussion also mentions that half of partipants used control strategies but that percentage is not reported in the results section either. Introduction • It should be made clear whether the paper focuses on Diabetes Type 2 or any type of diabetes. • Why is the ENSANUT 2012 reported as the last national health survey? Shouldn’t it be ENSANUT 2016? Methods • Line 71: I don’t think the word “considering” is appropriate here. I think the authors probably mean that the survey “achieved” a 91.7% response rate. Please, double check. • Line 86: Did these questions inquire about lifetime diagnosis or within a certain time window? • Lines 106-109: The decription of the DD score categorizatio into recommended and non-recommended foods is confusing. These dietary measures need to be explained more clearly. Perhaps some examples would help. • Lines 110-112: These measures of sleep and glycemic control strategies require more elaboration to increase the rigor of the study. The authors also need to specify if questions about glycemic control strategies were asked of all participants or only those who reported a diabetes diagnosis. If only those with diabetes were administered these questions, the n sizes should be added to the first row of Table 3. If this information was obtained from everyone, it would make sense to stratify the results about glycemic control by previous diagnosis of diabetes, as they can expect to vary significantly by disease status. Statistical Analyses • Please, unpack the variables used for adjustment, to increase replicability of the study. The list of variables adjusted for should also be reported as a footnote under Table 2. Results/Tables • It appears, per the 95% CI, that women with primary or less education were also more likely to be diagnosed with diabetes than their male counterparts, but this result is not reported. • The result reported for gender differences among those with overweight or obesity (Lines 128-129) seems at odds with the overlapping 95% CIs shown on Table 1. Is that result after adjustment for other factors? If so, this should be stated. • Table 1 should show the prevalence rates among those with and without the conditions listed under “Prior Medical Diagnosis”. That is, prevalence for those with and without a diagnosis of high blood pressure; with and without overweight or obesity; etc. • The reporting of results shown on Table 2 (Lines 145-151) can be significantly improved. I recommend reporting the results separately for women and men and being more systematic listing all of the factors that were statistically associated with a diabetes diagnosis after adjustiment for other confounders, instead of picking/choosing just a few. • I would like to see the results for all (women and men combined) on Table 2, just like Tables 1 and 3. If it’s difficult to fit all of the information on one table, the authors could consider presenting only adjusted results and provide the unadjusted ORs as supplemental material? • On Table 3, it is unclear what “no testing” means. As stated in one of my comments for the abstract, if 69.5% did not testing, how is it possible that 44.9% did venous blood sampling? This should be mutually exclusive categories, yet they add up to more than 100%. Discussion • Please, comment on how the estimated prevalence compares to estimates based on earlier ENSANUT surveys, to give a sense of any potential trends. • Lines 207-208: Please, double check and clarify why these percents exceed 100%. • Lines 211-212: Specify this statistic is for the U.S. • Lines 219-220: Clarify what “sub-diagnosis” means here and revise this sentence to make its meaning clearer. Is this about hypertension or about diabetes? • Lines 224-225: This sentence is unclear. Is this still based on ENSANUT 2016? Also, the issue of social desirability bias should be addressed separately, as part of the limitations, as it can apply to all of the self-report based data used for this analysis. • Line 231-233: The authors could cite other studies that have compared measured versus self-reported diabetes for Mexican adults, even if outside Mexico, as further evidence of likely undestimatio of true prevalence of diabetes. See Barcellos et al. Health Affairs 2012;31(12). • A paragraph with implications and/or recommendations for future research and practice would strengthen the discussion, as would adding a little bit of context regarding any national strategies to improve diabetes prevention and control. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
PONE-D-19-29166R1 Prevalence of previously diagnosed diabetes and glycemic control strategies in Mexican adults: ENSANUT-2016 PLOS ONE Dear M.Sc Ramirez-Villalobos, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Kindly address reviewer comment. We would appreciate receiving your revised manuscript by Apr 09 2020 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols Please include the following items when submitting your revised manuscript:
Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. We look forward to receiving your revised manuscript. Kind regards, Naeti Suksomboon Academic Editor PLOS ONE [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The authors have addressed most of my previous comments adequately and I think this revised version is a fine contribution to the literature. I only have a remaining concern regarding the dietary measure and a few, very minor additional comments that I would like to see addressed: • The description of the dietary measure is still unclear. I understand how the initial DD score was computed (number of food groups x number of days they were consumed) and the use of quartiles to create four groups from lowest to highest dietary diversity, but I am confused about the classification of food groups into desirable and not desirable. How was the classification of the food groups into these categories factored in when computing the DD score and quartiles? • I would like to see the findings regarding dietary diversity as a protective factor against a diabetes diagnoses reported in the results section and commented on the discussion. It seems to me this is an important result with implications for public health campaigns promoting dietary improvements. It is also interesting that the pattern of results for this factor is different for men and women, with a significant association for women, but not for men. • On Table 1, the estimates for individuals without kidney failure are missing. • On line 195, the “six” years appears incorrect. It should be 10 (if the reference point is 2006) or 4 (if the reference point is 2012). • On line 227, there seems to be a typo. I think the authors mean “…with hypertension who are unaware”. • The sentence on lines 259-261 needs to be revised to make sense. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 2 |
|
Prevalence of previously diagnosed diabetes and glycemic control strategies in Mexican adults: ENSANUT-2016 PONE-D-19-29166R2 Dear Dr. Ramirez-Villalobos, We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements. Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication. Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. With kind regards, Naeti Suksomboon Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: (No Response) ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: I have no further comments. All of my concerns have been adequately addressed in this revised version. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No |
| Formally Accepted |
|
PONE-D-19-29166R2 Prevalence of previously diagnosed diabetes and glycemic control strategies in Mexican adults: ENSANUT-2016 Dear Dr. Ramirez-Villalobos: I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. For any other questions or concerns, please email plosone@plos.org. Thank you for submitting your work to PLOS ONE. With kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Naeti Suksomboon Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .